RecruitingPhase 2
NCT05702229Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction…
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of no…
United States, China +5 more163 participantsStarted 2023-01-16Updated 2026-05-14 Treatment: Rilvegostomig, Volrustomig
RecruitingPhase 3
NCT06177041M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1…
Gastric/GEJ adenocarcinoma, which is one of the major leading causes of cancer-related deaths worldwide, is a global challenge to human health. However, standar…
China486 participantsStarted 2023-12-25Updated 2024-02-28 Treatment: M108 monoclonal antibody, Placebo